Moises Cossio, DO
Pulmonary Disease · Roanoke, VANPI 1265405260
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Actelion Pharmaceuticals US, Inc. accounts for 75.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $10,487 and has fallen 90.1% since, to $1,035 in 2025.
Across 129 payments — averaging $119.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$12K
- United Therapeutics Corporation$2K
- Inari Medical, Inc.$541
- Abbott$456
- Bayer$204
- Johnson & Johnson$153
- plus $624 from 8 others
Across 47 payments — averaging $2803.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$132K
What the payments were for
- Consulting fees$2,73018%
- Speaking & faculty fees$3,51023%
- Travel & lodging$2,09714%
- Food & beverage$6,66143%
- Education$3702%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 54 | $11,563 |
| United Therapeutics Corporation | 38 | $1,827 |
| Inari Medical, Inc. | 17 | $541 |
| Abbott | 4 | $456 |
| Bayer | 2 | $204 |
| Johnson & Johnson(2 entities) | 2 | $153 |
| Boehringer Ingelheim | 2 | $151 |
| Abiomed | 4 | $136 |
| Penumbra, Inc. | 1 | $119 |
| Genentech USA, Inc. | 1 | $76 |
| Liquidia Technologies, Inc. | 1 | $59 |
| GSK | 1 | $43 |
| Sandoz | 1 | $21 |
| Pharming Healthcare, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$4,751
- UPTRAVI$926
- REMODULIN$717
- ORENITRAM$717
- TYVASO$569
- CARDIOMEMS$282
- FLOWTRIEVER CATHETER, S$267
- CT THROMBECTOMY SYSTEM KIT$267
- Adempas$204
- CardioMEMS HF System$150
- STEEN Solution$144
- XARELTO$125
- Indigo System$119
How this compares
$15,369 in reported general payments places this provider in the 85th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 102 | $2,495,565 |
| OpsumitMacitentan | 148 | $1,901,569 |
| AdempasRiociguat | 86 | $1,166,518 |
| UptraviSelexipag | 14 | $329,496 |
| OfevNintedanib Esylate | 25 | $324,266 |
| JardianceEmpagliflozin | 137 | $107,119 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 108 | $54,538 |
| Ambrisentan | 15 | $42,489 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $35,833 |
| Tadalafil | 41 | $32,124 |
| Sildenafil Citrate | 86 | $30,991 |
| EliquisApixaban | 32 | $22,999 |
| Spiriva HandihalerTiotropium Bromide | 25 | $16,782 |
| Spiriva RespimatTiotropium Bromide | 23 | $11,883 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $11,563 | $2,231,065162 claims |
| BayerAdempas | $204 | $1,166,51886 claims |
| Boehringer IngelheimOfev, Jardiance, Spiriva Respimat | $151 | $443,268185 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Incruse Ellipta | $43 | $94,899160 claims |
| Johnson & JohnsonXarelto | $153 | $6,58913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Roanoke
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
- Ellen VolkerCharlottesville$177K
- Himanshu DesaiChesapeake$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.